JPH042984Y2 - - Google Patents

Info

Publication number
JPH042984Y2
JPH042984Y2 JP1983035448U JP3544883U JPH042984Y2 JP H042984 Y2 JPH042984 Y2 JP H042984Y2 JP 1983035448 U JP1983035448 U JP 1983035448U JP 3544883 U JP3544883 U JP 3544883U JP H042984 Y2 JPH042984 Y2 JP H042984Y2
Authority
JP
Japan
Prior art keywords
fiber layer
indomethacin
ethanol
polyethylene glycol
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP1983035448U
Other languages
Japanese (ja)
Other versions
JPS59141532U (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JP3544883U priority Critical patent/JPS59141532U/en
Publication of JPS59141532U publication Critical patent/JPS59141532U/en
Application granted granted Critical
Publication of JPH042984Y2 publication Critical patent/JPH042984Y2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【考案の詳細な説明】 本案は筋肉痛、ロイマチス、神経痛等の治療、
予防等に使用する医療用貼付剤に関する。
[Detailed explanation of the invention] This invention is for the treatment of muscle pain, leumatis, neuralgia, etc.
Related to medical patches used for prevention, etc.

本案は、筋肉痛等に有効なインドメタシンをエ
タノールとポリエチレングリコールの混合溶液に
溶解して繊維層に担持させることによつて、イン
ドメタシンを徐々に経皮投与し、薬効の持続時間
を長くすることなど、効果的な投与ができるよう
にしようとするものである。
This project involves dissolving indomethacin, which is effective for muscle pain, etc., in a mixed solution of ethanol and polyethylene glycol and supporting it on the fiber layer, thereby gradually administering indomethacin transdermally and prolonging the duration of its medicinal effects. The aim is to enable effective administration.

本案の実施例について説明すると、不織布、織
布、プラスチツクフイルム、アルミニユーム箔積
層フイルムその他の材料で適宜形状に形成された
基材1の上面の全部若しくは中央部を残して周縁
部区帯にアクリル系、ゴム系、ビニルエーテル
系、シリコーン系その他の粘着剤からなる貼付材
層2を設け、その中央部区帯に織布、不織布、フ
リース、スライバーその他の形成された繊維層3
をその周縁部に前記貼付材層を存して設け、前記
繊維層には、インドメタシンをエタノールとポリ
エチレングリコールの混合溶剤にとかして得られ
る適宜濃度のインドメタシン溶液4を含浸担持さ
せ、この薬剤溶液含有繊維層の上面には前記貼付
材層に対し剥離性な被覆5を設け、その周縁部を
前記繊維層の外側に露出している貼付材層に被着
している。
To explain the embodiment of the present invention, the base material 1 is made of non-woven fabric, woven fabric, plastic film, aluminum foil laminated film, or other material and is formed into an appropriate shape. A patch layer 2 made of a rubber-based, vinyl ether-based, silicone-based or other adhesive is provided, and a fibrous layer 3 of woven fabric, non-woven fabric, fleece, sliver, or other material is formed in the central zone.
is provided with the patch layer on its periphery, and the fibrous layer is impregnated and supported with an indomethacin solution 4 of an appropriate concentration obtained by dissolving indomethacin in a mixed solvent of ethanol and polyethylene glycol, and this drug solution-containing A releasable coating 5 is provided on the upper surface of the fibrous layer with respect to the patch layer, and its peripheral portion is applied to the patch layer exposed to the outside of the fibrous layer.

上記繊維層を構成する繊維は綿、レーヨン、ポ
リビニルアルコール、ポリエステルその他の繊維
があるが、レーヨンその他の吸水性繊維は薬剤溶
液の保持性がすぐれ好適であり、合成繊維等の非
吸水性繊維と混合して薬剤の放出性を適度に調節
できる。
The fibers constituting the above fiber layer include cotton, rayon, polyvinyl alcohol, polyester, and other fibers, but rayon and other water-absorbing fibers are suitable because of their excellent ability to retain drug solutions, and they are suitable for use with non-water-absorbing fibers such as synthetic fibers. By mixing, the release properties of the drug can be appropriately adjusted.

上記繊維層の外側の貼付材層はこの例では粘着
剤の層を使用しているが、これは剥離性被覆5を
安定に仮着できると共に貼付剤を皮膚上に安定に
保定できるように形成され、又基材は適当な柔軟
性、伸縮性を有するプラスチツクフイルム、アル
ミニウム箔等を積層したプラスチツクフイルムそ
の他のフイルム、不織布その他の布帛、加工紙等
が必要に応じて適宜使用できるほか、剥離性被覆
5も前記基材と同様な材料で形成できる。
In this example, an adhesive layer is used as the patch layer outside the fiber layer, which is formed so that the releasable coating 5 can be stably attached temporarily and the patch can be stably held on the skin. In addition, as the base material, plastic films with appropriate flexibility and stretchability, plastic films laminated with aluminum foil, other films, nonwoven fabrics and other fabrics, processed paper, etc. can be used as appropriate, and peelable The coating 5 can also be made of the same material as the base material.

図示の貼付剤6は、径約50mmの円形状のポリプ
ロピレンフイルムの基材1の上面に厚さ約40μの
アクリル系粘着剤からなる貼付材層を形成し、そ
の中央部に繊維層3として径約40mm、厚さ約0.5
mmのレーヨン不織布を載せ、これにインドメタシ
ン1%溶液(ポリエチレングリコール400とエタ
ノールを80:19の割合の混合溶剤溶液)41gを
含浸させ、その上にポリエステルフイルム5を被
着している。この貼付剤をうさぎの剪毛した背中
に貼り、血液中のインドメタシンの濃度を経時的
に測定した結果はつぎの如くであつて、薬剤の経
皮吸収が適度に行なわれることが判る。
The illustrated patch 6 has a patch layer made of an acrylic adhesive with a thickness of about 40 μm formed on the top surface of a circular polypropylene film base material 1 with a diameter of about 50 mm, and a fiber layer 3 with a diameter of about 40 μm in the center. Approximately 40mm, thickness approximately 0.5
A rayon nonwoven fabric of 5 mm in diameter was placed on it, impregnated with 41 g of a 1% solution of indomethacin (a mixed solvent solution of polyethylene glycol 400 and ethanol in a ratio of 80:19), and a polyester film 5 was placed thereon. This patch was applied to the shaved back of a rabbit, and the concentration of indomethacin in the blood was measured over time. The results are as follows, indicating that the drug is appropriately absorbed through the skin.

貼付後経過時間 血漿中の薬剤量 2時間 400μg/ml 4時間 300 〃 12時間 100 〃 上記の如く形成された貼付剤は一箇乃至数個等
の適当数を不透過性材料で密封して市販に供する
ことができる。
Time elapsed after application Amount of drug in plasma 2 hours 400μg/ml 4 hours 300 〃 12 hours 100 〃 The patch formed as above is sold in an appropriate number, such as one or several, sealed with an impermeable material. It can be provided to

本案によれば、インドメタシンを溶かしたエタ
ノールが、これに比べて溶かし難いポリエチレン
グリコールの間に分散状態に位置しているので、
インドメタシンを溶解した溶液が繊維層から揮散
して行くこともなく、しかもポリエチレングリコ
ールの有する適度の粘性によつて繊維層に安定的
に保持される。
According to this proposal, the ethanol in which indomethacin is dissolved is located in a dispersed state between polyethylene glycol, which is difficult to dissolve compared to ethanol.
The solution in which indomethacin is dissolved does not volatilize from the fiber layer, and is stably retained in the fiber layer due to the appropriate viscosity of polyethylene glycol.

この貼付剤を皮膚等に貼付けると、インドメタ
シンはエタノールに溶けた状態で、エタノールと
共に皮膚を通つて吸収されて行くが、このエタノ
ールは上記の如くポリエチレングリコールの間に
分散された状態になつているので、このエタノー
ルはポリエチレングリコールによつて適度に経皮
量が規制されて、徐々に経皮されて行くから、イ
ンドメタシンは適量づつ長時間に渡つて投与する
ことができ、その薬効を持続させることができ、
筋肉痛、ロイマチス、神経痛その他の疾患の治
療、予防等に極めて有効である。そして、このエ
タノールとポリエチレングリコールの混合比率を
変えるようにすると、ポリエチレングリコールに
よる上記投与量の規制の程度が変るので、インド
メタシンの単位時間当りの投与量、経皮吸収速
度、投与持続時間等を変化させることができる。
When this patch is applied to the skin, indomethacin is dissolved in ethanol and absorbed through the skin along with the ethanol, but this ethanol becomes dispersed between polyethylene glycol as described above. The transdermal dose of this ethanol is moderately regulated by polyethylene glycol, and it is gradually passed through the skin, so indomethacin can be administered in appropriate doses over a long period of time, maintaining its medicinal efficacy. It is possible,
It is extremely effective in the treatment and prevention of muscle pain, leumatis, neuralgia and other diseases. If the mixing ratio of ethanol and polyethylene glycol is changed, the degree of regulation of the above-mentioned dosage by polyethylene glycol will change, so the dosage per unit time, transdermal absorption rate, administration duration, etc. of indomethacin will be changed. can be done.

【図面の簡単な説明】[Brief explanation of the drawing]

図面は本案の実施例を示し、第1図は平面図、
第2図は第1図の−線断面図、第3図は変形
例を示す平面図である。 1は基板、2は貼付材層、3は繊維層、4は薬
剤溶液、5は剥離性被覆である。
The drawings show an embodiment of the present invention, and FIG. 1 is a plan view;
FIG. 2 is a sectional view taken along the line -- in FIG. 1, and FIG. 3 is a plan view showing a modification. 1 is a substrate, 2 is a patch layer, 3 is a fiber layer, 4 is a drug solution, and 5 is a peelable coating.

Claims (1)

【実用新案登録請求の範囲】 1 基材を有し、該基材の上面の少くとも周面部
に貼付材層を形成し、その上に繊維層を設け、
該繊維層にインドメタシンをポリエチレングリ
コールとエタノールの混合溶剤に溶かした溶液
を含浸させ、上記繊維層の上から剥離性フイル
ムの被覆を貼着した医療用貼付剤。 2 ポリエチレングリコール400とエタノールが
80:19で混合された溶剤で作られたインドメタ
シン1%溶液を繊維層に含浸させている実用新
案登録請求の範囲第1項に記載の医療用貼付
剤。 3 上記繊維層が不織布で形成されている実用新
案登録請求の範囲第1項または第2項に記載の
医療用貼付剤。 4 上記繊維層は吸水性繊維と非吸水性繊維が混
合されて形成されている実用新案登録第1項〜
第3項のいずれかに記載の医療用貼付剤。
[Claims for Utility Model Registration] 1. Having a base material, forming an adhesive layer on at least the peripheral surface of the upper surface of the base material, and providing a fiber layer thereon,
A medical patch comprising: the fiber layer impregnated with a solution of indomethacin dissolved in a mixed solvent of polyethylene glycol and ethanol, and a peelable film covering applied over the fiber layer. 2 Polyethylene glycol 400 and ethanol
The medical patch according to claim 1, wherein the fiber layer is impregnated with a 1% solution of indomethacin made from a solvent mixed at a ratio of 80:19. 3. The medical patch according to claim 1 or 2, wherein the fiber layer is formed of a nonwoven fabric. 4 The above-mentioned fiber layer is formed by a mixture of water-absorbing fibers and non-water-absorbing fibers Utility model registration item 1~
The medical patch according to any of paragraph 3.
JP3544883U 1983-03-14 1983-03-14 medical patch Granted JPS59141532U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3544883U JPS59141532U (en) 1983-03-14 1983-03-14 medical patch

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3544883U JPS59141532U (en) 1983-03-14 1983-03-14 medical patch

Publications (2)

Publication Number Publication Date
JPS59141532U JPS59141532U (en) 1984-09-21
JPH042984Y2 true JPH042984Y2 (en) 1992-01-31

Family

ID=30166145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3544883U Granted JPS59141532U (en) 1983-03-14 1983-03-14 medical patch

Country Status (1)

Country Link
JP (1) JPS59141532U (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784857A (en) * 1986-06-03 1988-11-15 Smith And Nephew Associated Companies Plc Drug delivery device, its preparation and use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56100716A (en) * 1980-01-16 1981-08-12 Nitto Electric Ind Co Ltd Drug administration member

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56100716A (en) * 1980-01-16 1981-08-12 Nitto Electric Ind Co Ltd Drug administration member

Also Published As

Publication number Publication date
JPS59141532U (en) 1984-09-21

Similar Documents

Publication Publication Date Title
EP0227836B1 (en) Sustained releasing patch
AU599080B2 (en) Sustained release pharmaceutical preparation
DK175077B1 (en) Transdermal therapeutic system, method of preparation thereof and use thereof
FI89243C (en) Therapeutic system and procedure for its employment
US5306503A (en) Patch with a high content of softening ingredients
US6791003B1 (en) Dual adhesive transdermal drug delivery system
US4915950A (en) Printed transdermal drug delivery device
US4655768A (en) Bandage for sustained delivery of drugs
US6139868A (en) Transdermal therapeutic system, its use and production process
RU2052997C1 (en) Transdermal therapeutic system for medicinal agent application and a method of its preparing
JP5591685B2 (en) Transdermal absorption preparation
JPS63501075A (en) Verapamil transdermal delivery device
KR910002250B1 (en) Plaster containing active ingredients for controlles administration of active ingredients to the skin
US20120157937A1 (en) Transdermal therapeutic system provided with improved long-term carrying comfort
JP2004521085A (en) Transdermal delivery system capable of titration
CN112206223A (en) System for transdermal delivery of active substances
JPS6049601B2 (en) treatment device
US6110488A (en) Transdermal therapeutic system, its use and production process
JPH042984Y2 (en)
JPH05271056A (en) Controlled powdery agent for transcutaneous administration
CA1253805A (en) Bandage for sustained delivery of drugs
US6117448A (en) Transdermal therapeutic system, its use and production process
JP2557046B2 (en) Layered formulation
JPH07277961A (en) Percutaneous absorption preparation
JP2697191B2 (en) Transdermal formulation